Dr. Sender Liberman, MD
Claim this profileMcGill University Health Centre
Studies Colorectal Cancer
Studies Crohn's Disease
6 reported clinical trials
6 drugs studied
Affiliated Hospitals
Clinical Trials Sender Liberman, MD is currently running
Extended Mesenteric Excision
for Crohn's Disease
The study is looking at the role of the mesentery in disease recurrence for ileocolic Crohn's disease. It is a prospective study that has been designed to perform extended mesenteric excision on patients undergoing their first ileocolic resection for Crohn's disease. Endoscopic recurrence will be monitored with the hypothesis that patients receiving extended mesenteric ileocolic resection will have reduced endoscopic recurrence at 6 months after resection. (limited mesenteric resection).
Recruiting1 award N/A4 criteria
Early Ileostomy Closure
for Rectal Cancer
Our preliminary work demonstrates that there is buy-in from both patients and surgeons with regards to early ileostomy closure (EIC) for select rectal cancer patients undergoing restorative proctectomy (RP) and diverting loop ileostomy (DLI). The feedback from leaders in Europe further supports the need for a large scale randomized-controlled trial (RCT) on this subject in North America. Should the results of such a study be favourable, we believe it could support a change in practice that would be beneficial to patients and the health care system alike. Furthermore, our work will help identify which patients and practices are suitable for EIC. The goal of our project is to determine whether EIC in rectal cancer patients undergoing RP with a DLI is safe, feasible and beneficial in a North American population. Specifically, our primary objective is to compare the severity of complications between patients undergoing EIC versus traditional (late) closure. Our secondary objectives include assessing the difference in quality of life (QoL), early and late bowel function, and cost of care between these two groups.
Recruiting1 award N/A
More about Sender Liberman, MD
Clinical Trial Related4 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Sender Liberman, MD has experience with
- Extended Mesenteric Resection
- Extensive Mesentery Resection
- Patient Activation Booklet And Nursing Support
- Transanal Irrigation
- Early Ileostomy Closure
- Prehabilitation Program
Breakdown of trials Sender Liberman, MD has run
Colorectal Cancer
Crohn's Disease
Recurrence
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Sender Liberman, MD specialize in?
Sender Liberman, MD focuses on Colorectal Cancer and Crohn's Disease. In particular, much of their work with Colorectal Cancer has involved treating patients, or patients who are undergoing treatment.
Is Sender Liberman, MD currently recruiting for clinical trials?
Yes, Sender Liberman, MD is currently recruiting for 3 clinical trials in Montreal Quebec. If you're interested in participating, you should apply.
Are there any treatments that Sender Liberman, MD has studied deeply?
Yes, Sender Liberman, MD has studied treatments such as Extended Mesenteric Resection, Extensive mesentery resection, Patient Activation Booklet and nursing support.
What is the best way to schedule an appointment with Sender Liberman, MD?
Apply for one of the trials that Sender Liberman, MD is conducting.
What is the office address of Sender Liberman, MD?
The office of Sender Liberman, MD is located at: McGill University Health Centre, Montreal, Quebec H3G 1A4 Canada. This is the address for their practice at the McGill University Health Centre.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.